Bridge Medicines

United States
Sioux Falls, South Dakota, United States, 57104

Company profile

Bridge Medicines company profile

Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes an unbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
57104
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
2
Total equity funding
$10M
Last funding
Series Unknown / $10M / 2020-11-13
Last equity funding
Series Unknown / $10M
Investors
3
Lead investors
3
Articles
8

Categories and groups

Founders and investors

Lead investors

Bay City CapitalDeerfieldTakeda

Investors

Bay City CapitalDeerfieldTakeda